15,476 Shares in Tempus AI, Inc. $TEM Bought by Odyssean LLC

Key Points

• Odyssean LLC purchased 15,476 Tempus AI shares worth approximately $897,000, while institutional investors collectively own 24.22% of the company.
• Analyst sentiment is mixed: nine analysts rate the stock a Buy, six Hold, and two Sell. The average rating is Hold, with an average price target of $65.69.
• Tempus AI exceeded quarterly earnings and revenue expectations, reporting a loss of $0.04 per share on $382.49 million in revenue, up 21.6% year over year, though the company remains unprofitable.

Odyssean LLC purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 15,476 shares of the company's stock, valued at approximately $897,000.

Several other hedge funds and other institutional investors have also made changes to their positions in TEM. Royal Bank of Canada grew its position in shares of Tempus AI by 201.2% during the first quarter. Royal Bank of Canada now owns 25,988 shares of the company's stock worth $1,253,000 after buying an additional 17,359 shares in the last quarter. Rhumbline Advisers acquired a new stake in Tempus AI in the first quarter valued at approximately $116,000. Prudential Financial Inc. purchased a new position in Tempus AI in the second quarter worth approximately $276,000. Russell Investments Group Ltd. lifted its stake in Tempus AI by 21.3% in the second quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company's stock worth $415,000 after acquiring an additional 1,146 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in Tempus AI by 2,926.6% during the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company's stock worth $13,446,000 after acquiring an additional 204,629 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Guggenheim increased their price objective on shares of Tempus AI from $60.00 to $65.00 and gave the company a "buy" rating in a research report on Thursday, July 16th. Needham & Company LLC reiterated a "buy" rating and set a $75.00 target price on shares of Tempus AI in a research note on Friday, July 31st. Lake Street Capital downgraded shares of Tempus AI to a "hold" rating in a research note on Monday, July 20th. Stifel Nicolaus dropped their target price on Tempus AI from $60.00 to $50.00 and set a "hold" rating on the stock in a report on Monday, August 3rd. Finally, Weiss Ratings upgraded Tempus AI from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 12th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $65.69.

Tempus AI Stock Performance

Shares of TEM opened at $68.48 on Thursday. The stock has a 50 day moving average price of $53.97 and a 200 day moving average price of $51.60. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The company has a market capitalization of $12.36 billion, a price-to-earnings ratio of -47.56 and a beta of 3.58. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to analysts' expectations of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm's revenue for the quarter was up 21.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.22) earnings per share. Research analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Insider Activity at Tempus AI

In related news, EVP Andrew Polovin sold 22,148 shares of Tempus AI stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the sale, the executive vice president directly owned 146,067 shares in the company, valued at $7,246,383.87. This trade represents a 13.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 41,095 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the completion of the sale, the chief executive officer directly owned 562,463 shares of the company's stock, valued at approximately $27,903,789.43. This trade represents a 6.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 791,238 shares of company stock valued at $39,653,732. Corporate insiders own 24.26% of the company's stock.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source